These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 16091363)
1. Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. Zhu Z; Ramos J; Kampa K; Adimoolam S; Sirisawad M; Yu Z; Chen D; Naumovski L; Lopez CD J Biol Chem; 2005 Oct; 280(41):34473-80. PubMed ID: 16091363 [TBL] [Abstract][Full Text] [Related]
2. Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Chen D; Padiernos E; Ding F; Lossos IS; Lopez CD Cell Death Differ; 2005 Apr; 12(4):358-68. PubMed ID: 15592436 [TBL] [Abstract][Full Text] [Related]
3. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590 [TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553 [TBL] [Abstract][Full Text] [Related]
5. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664 [TBL] [Abstract][Full Text] [Related]
6. Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma. Liu K; Jiang T; Ouyang Y; Shi Y; Zang Y; Li N; Lu S; Chen D Oncotarget; 2015 Jun; 6(18):16507-16. PubMed ID: 25980493 [TBL] [Abstract][Full Text] [Related]
7. NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. Waku T; Nakamura N; Koji M; Watanabe H; Katoh H; Tatsumi C; Tamura N; Hatanaka A; Hirose S; Katayama H; Tani M; Kubo Y; Hamazaki J; Hamakubo T; Watanabe A; Murata S; Kobayashi A Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123008 [TBL] [Abstract][Full Text] [Related]
8. The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Yerlikaya A; Okur E; Ulukaya E Tumour Biol; 2012 Oct; 33(5):1385-92. PubMed ID: 22477712 [TBL] [Abstract][Full Text] [Related]
9. Expression of heme oxygenase-1 in response to proteasomal inhibition. Yerlikaya A Protein Pept Lett; 2012 Dec; 19(12):1330-3. PubMed ID: 22670665 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Tsapakidis K; Vlachostergios PJ; Voutsadakis IA; Befani CD; Patrikidou A; Hatzidaki E; Daliani DD; Moutzouris G; Liakos P; Papandreou CN Int J Urol; 2012 Jun; 19(6):565-74. PubMed ID: 22324515 [TBL] [Abstract][Full Text] [Related]
11. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation. Bergamaschi D; Samuels Y; Zhong S; Lu X Oncogene; 2005 May; 24(23):3836-41. PubMed ID: 15782125 [TBL] [Abstract][Full Text] [Related]
12. New insights into the expanding complexity of the tumor suppressor ASPP2. Kampa KM; Bonin M; Lopez CD Cell Cycle; 2009 Sep; 8(18):2871-6. PubMed ID: 19657229 [TBL] [Abstract][Full Text] [Related]
13. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Hur J; Bell DW; Dean KL; Coser KR; Hilario PC; Okimoto RA; Tobey EM; Smith SL; Isselbacher KJ; Shioda T Cancer Res; 2006 Oct; 66(20):10153-61. PubMed ID: 17047080 [TBL] [Abstract][Full Text] [Related]
14. Proapoptotic fibronectin fragment induces the degradation of ubiquitinated p53 via proteasomes in periodontal ligament cells. Ghosh A; Joo NE; Chen TC; Kapila YL J Periodontal Res; 2010 Aug; 45(4):481-7. PubMed ID: 20337881 [TBL] [Abstract][Full Text] [Related]
15. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Yu J; Tiwari S; Steiner P; Zhang L Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479 [TBL] [Abstract][Full Text] [Related]
16. ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy. Shi Y; Han Y; Xie F; Wang A; Feng X; Li N; Guo H; Chen D J Cell Mol Med; 2015 Mar; 19(3):535-43. PubMed ID: 25534115 [TBL] [Abstract][Full Text] [Related]
17. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676 [TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. Ling YH; Liebes L; Zou Y; Perez-Soler R J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677 [TBL] [Abstract][Full Text] [Related]
19. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21. Shen Y; Lu L; Xu J; Meng W; Qing Y; Liu Y; Zhang B; Hu H Cell Biol Int; 2013 Oct; 37(10):1114-21. PubMed ID: 23716467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]